
Conformis CFMS
Quarterly report 2023-Q2
added 08-02-2023
Conformis Total Assets 2011-2026 | CFMS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Conformis
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 94 M | 145 M | 71.5 M | 72.4 M | 63 M | 93.8 M | 113 M | 159 M | 71.3 M | 83.9 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 159 M | 63 M | 96.7 M |
Quarterly Total Assets Conformis
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.8 M | 81.9 M | 94 M | 105 M | 117 M | 129 M | 145 M | 158 M | 169 M | 146 M | 71.5 M | 71.5 M | 71.5 M | 71.5 M | 72.4 M | 72.4 M | 72.4 M | 72.4 M | 63 M | 63 M | 63 M | 63 M | 93.8 M | 93.8 M | 93.8 M | 93.8 M | 113 M | 113 M | 113 M | 113 M | 159 M | 159 M | 159 M | 159 M | 71.3 M | 71.3 M | 71.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 169 M | 63 M | 100 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 12.0 | -0.58 % | $ 1.62 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 9.15 | -2.51 % | $ 259 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
5.81 B | $ 36.35 | -1.05 % | $ 5.42 K | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 15.71 | -1.44 % | $ 369 M | ||
|
EDAP TMS S.A.
EDAP
|
91.5 M | $ 3.4 | -1.73 % | $ 127 M | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
6.21 B | $ 168.12 | -2.18 % | $ 12.6 B | ||
|
AxoGen
AXGN
|
222 M | $ 31.05 | -4.87 % | $ 1.43 B | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
256 M | $ 4.01 | -2.91 % | $ 849 M | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.61 | 3.37 % | $ 38 M | ||
|
TELA Bio
TELA
|
81.4 M | $ 0.69 | 9.81 % | $ 32.4 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
124 M | $ 9.65 | -0.52 % | $ 346 M | ||
|
FONAR Corporation
FONR
|
199 M | $ 18.58 | -0.11 % | $ 122 M | ||
|
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 61.35 | -1.93 % | $ 90.8 B | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 11.1 | 1.19 % | $ 1.67 B | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 34.34 | 0.81 % | $ 1.07 B | ||
|
Globus Medical
GMED
|
5.3 B | $ 90.53 | 2.15 % | $ 12.2 B | ||
|
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 80.81 | -0.42 % | $ 47.3 B | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 1.76 | -7.37 % | $ 1.07 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 9.31 | - | $ 717 M | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 54.8 | 1.25 % | $ 1.61 B | ||
|
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.0 | 0.34 % | $ 16.9 M | ||
|
Integer Holdings Corporation
ITGR
|
3.41 B | $ 85.37 | -0.29 % | $ 2.97 B | ||
|
LENSAR
LNSR
|
71.4 M | $ 5.84 | -0.85 % | $ 69.8 M | ||
|
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
91.7 B | $ 86.48 | 0.22 % | $ 111 B | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
38.6 M | $ 0.67 | -4.29 % | $ 28 M | ||
|
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M |